Added diagnostic value of cerebrospinal fluid biomarkers for differential dementia diagnosis in an autopsy-confirmed cohort
Open accessAbstract
BACKGROUND: Differential dementia diagnosis remains a challenge due to overlap of clinical profiles, which often results in diagnostic doubt. OBJECTIVE: Determine the added diagnostic value of cerebrospinal fluid (CSF) biomarkers for differential dementia diagnosis as compared to autopsy-confirmed diagnosis. METHODS: Seventy-one dementia patients with autopsy-confirmed diagnoses were included in this study. All neuropathological diagnoses were established according to standard neuropathological criteria and consisted of Alzheimer's disease (AD) or other dementias (NONAD). CSF levels of Aβ1 - 42, T-tau, and P-tau181 were determined and interpreted based on the IWG-2 and NIA-AA criteria, separately. A panel of three neurologists experienced with dementia made clinical consensus dementia diagnoses. Clinical and CSF biomarker diagnoses were compared to the autopsy-confirmed diagnoses. RESULTS: Forty-two patients (59%) had autopsy-confirmed AD, whereas 29 patients (41%) had autopsy-confirmed NONAD. Of the 24 patients with an ambiguous clinical dementia diagnosis, a correct diagnosis would have been established in 67% of the cases applying CSF biomarkers in the context of the IWG-2 or the NIA-AA criteria respectively. CONCLUSION: AD CSF biomarkers have an added diagnostic value in differential dementia diagnosis and can help establishing a correct dementia diagnosis in case of ambiguous clinical dementia diagnoses.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In both situations-Alzheimer's disease with other brain pathologies and Alzheimer-type lesions as copathology in other neurodegenerative diseases-pathophysiological Alzheimer's disease biomarkers can be positive.
“In both situations, pathophysiological Alzheimer’s disease biomarkers can be positive.111”
From Clinical diagnosis of Alzheimer’s disease: Recommendations of the International Working Group (2021) · cites this paper as [111]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915 · see citing works
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657 · see citing works
Parkinsonism: onset, progression, and mortality
Hoehn, M. M., & Yahr, M. D. (1967) · Neurology · doi:10.1212/wnl.17.5.427 · Cited by 12,107 · cited 1× · see citing works
“Idiopathic PD was diagnosed based on the presence of at least two out of four motor manifestations that characterize the disease and an insidious onset [14].”
BackgroundDiagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium
McKeith, I. G., Dickson, D. W., Lowe, J., Emre, M., O'Brien, J. T., Feldman, H., Cummings, J., Duda, J. E., Lippa, C., Perry, E. K., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000187889.17253.b1 · Cited by 5,069 · see citing works
Frontotemporal lobar degeneration: A consensus on clinical diagnostic criteria
Neary, D., Snowden, J. S., Gustafson, L., Passant, U., Stuss, D., Black, S., Freedman, M., Kertesz, A., Robert, P. H., Albert, M., et al. (1998) · Neurology · doi:10.1212/wnl.51.6.1546 · Cited by 5,047 · see citing works
Román, G. C., Tatemichi, T. K., Erkinjuntti, T., Cummings, J. L., Masdeu, J. C., Garcia, J. H., Amaducci, L., Orgogozo, J.-M., Brun, A., Hofman, A., et al. (1993) · Neurology · doi:10.1212/wnl.43.2.250 · Cited by 4,921 · see citing works
Overdependence on degraded gist memory in Alzheimer's disease.
Gallo, D. A., Shahid, K. R., Olson, M. A., Solomon, T. M., Schacter, D. L., & Budson, A. E. (2006) · Neuropsychology · doi:10.1037/0894-4105.20.6.625 · Cited by 4,756 · see citing works
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
Dubois, B., Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. L., Blennow, K., DeKosky, S. T., Gauthier, S., Selkoe, D., Bateman, R., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70090-0 · Cited by 3,321 · see citing works
Self-citationWeıntraub, S. (1990) · Archives of Neurology · doi:10.1001/archneur.1990.00530120075013 · Cited by 3,012 · see citing works
Montine, T. J., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Dickson, D. W., Duyckaerts, C., Frosch, M. P., Masliah, E., Mirra, S. S., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-011-0910-3 · Cited by 2,992 · see citing works
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065 · see citing works
Cerebrospinal fluid and plasma biomarkers in Alzheimer disease
Blennow, K., Hampel, H., Weiner, M., & Zetterberg, H. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.4 · Cited by 1,863 · see citing works
Hansson, O., Zetterberg, H., Buchhave, P., Londos, E., Blennow, K., & Minthon, L. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70355-6 · Cited by 1,700 · see citing works
Cairns, N. J., Bigio, E. H., Mackenzie, I. R. A., Neumann, M., Lee, V. M.-Y., Hatanpaa, K. J., White, C. L., Schneider, J. A., Grinberg, L. T., Halliday, G., et al. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0237-2 · Cited by 1,110 · see citing works
A harmonized classification system for FTLD-TDP pathology
Mackenzie, I. R., Neumann, M., Baborie, A., Sampathu, D. M., du Plessis, D., Jaros, E., Perry, R. H., Trojanowski, J. Q., Mann, D. M. A., & Lee, V. M. ‐. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0845-8 · Cited by 1,013 · see citing works
Mackenzie, I. R. A., Neumann, M., Bigio, E. H., Cairns, N. J., Alafuzoff, I., Kril, J., Kovacs, G. G., Ghetti, B., Halliday, G., Holm, I. E., et al. (2010) · Acta Neuropathologica · doi:10.1007/s00401-009-0612-2 · Cited by 1,012 · see citing works
Clark, C. M., Pontecorvo, M. J., Beach, T. G., Bedell, B. J., Coleman, R. E., Doraiswamy, P. M., Fleisher, A. S., Reiman, E. M., Sabbagh, M. N., Sadowsky, C. H., et al. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70142-4 · Cited by 855 · see citing works
Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort
Schoonenboom, N. S. M., Reesink, F. E., Verwey, N. A., Kester, M. I., Teunissen, C. E., van de Ven, P. M., Pijnenburg, Y. A. L., Blankenstein, M. A., Rozemuller, A. J., Scheltens, P., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e31823ed0f0 · Cited by 302 · see citing works
Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia
Engelborghs, S., de Vreese, K., de Casteele, T. V., Vanderstichele, H., Everbroeck, B. V., Cras, P. P., Martin, J., Vanmechelen, E., & Deyn, P. P. D. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.02.016 · Cited by 256 · see citing works
Self-citationRowe, C. C., Bourgeat, P., Ellis, K. A., Brown, B., Lim, Y. Y., Mulligan, R., Jones, G., Maruff, P., Woodward, M., Price, R., et al. (2013) · Annals of Neurology · doi:10.1002/ana.24040 · Cited by 222 · see citing works
CSF biomarkers cutoffs: The importance of coincident neuropathological diseases
Toledo, J. B., Brettschneider, J., Grossman, M., Arnold, S. E., Hu, W. T., Xie, S. X., Lee, V. M.-Y., Shaw, L. M., & Trojanowski, J. Q. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-0983-7 · Cited by 182 · see citing works
Lattanzio, F., Abu‐Rumeileh, S., Franceschini, A., Kai, H., Amore, G., Poggiolini, I., Rossi, M., Baiardi, S., McGuire, L. I., Ladogana, A., et al. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1683-0 · Cited by 163 · see citing works
Herukka, S.-K., Simonsen, A. H., Andreasen, N., Baldeiras, I., Bjerke, M., Blennow, K., Engelborghs, S., Frisoni, G. B., Gabryelewicz, T., Galluzzi, S., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.09.009 · Cited by 141 · see citing works
Self-citationRecommendations for CSF AD biomarkers in the diagnostic evaluation of dementia
Simonsen, A. H., Herukka, S.-K., Andreasen, N., Baldeiras, I., Bjerke, M., Blennow, K., Engelborghs, S., Frisoni, G. B., Gabryelewicz, T., Galluzzi, S., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.09.008 · Cited by 138 · see citing works
Self-citationKapaki, E. (2001) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.71.3.401 · Cited by 134 · see citing works
der Mussele, S. V., Fransén, E., Struyfs, H., Luyckx, J., Mariën, P., Saerens, J., Somers, N., Goeman, J., Deyn, P. P. D., & Engelborghs, S. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-140405 · Cited by 132 · see citing works
Self-citationNiemantsverdriet, E., Ottoy, J., Somers, C., Roeck, E. E. D., Struyfs, H., Soetewey, F., Verhaeghe, J. A. J., den Bossche, T. V., Mossevelde, S. V., Goeman, J., et al. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170327 · Cited by 94 · see citing works
Self-citationSlaets, S., Bastard, N. L., Martin, J., Sleegers, K., Broeckhoven, C. V., Deyn, P. P. D., & Engelborghs, S. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-130107 · Cited by 87 · see citing works
Self-citationAdded diagnostic value of CSF biomarkers in differential dementia diagnosis
Bastard, N. L., Martin, J., Vanmechelen, E., Vanderstichele, H., Deyn, P. P. D., & Engelborghs, S. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.10.017 · Cited by 67 · see citing works
Self-citationAmyloid Pathology Influences Aβ1-42 Cerebrospinal Fluid Levels in Dementia with Lewy Bodies
Slaets, S., Bastard, N. L., Theuns, J., Sleegers, K., Verstraeten, A., Leenheir, E. D., Luyckx, J., Martin, J., Broeckhoven, C. V., & Engelborghs, S. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-122176 · Cited by 54 · see citing works
Self-citationDiagnostic value of CSF protein profile in a Portuguese population of sCJD patients
Baldeiras, I., Ribeiro, M. H., Pacheco, P. R., Machado, Á. S., Santana, I. J., Cunha, L., & Oliveira, C. R. (2009) · Journal of Neurology · doi:10.1007/s00415-009-5160-0 · Cited by 53 · see citing works
Cerebrospinal Fluid P-Tau181P: Biomarker for Improved Differential Dementia Diagnosis
Struyfs, H., Niemantsverdriet, E., Goossens, J., Fransén, E., Martin, J., Deyn, P. P. D., & Engelborghs, S. (2015) · Frontiers in Neurology · doi:10.3389/fneur.2015.00138 · Cited by 52 · see citing works
Self-citationA Decade of Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease in Belgium
Somers, C., Struyfs, H., Goossens, J., Niemantsverdriet, E., Luyckx, J., Roeck, N. D., Roeck, E. E. D., Vil, B. B. D., Cras, P. P., Martin, J., et al. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-151097 · Cited by 50 · see citing works
Self-citationOverdiagnosing Vascular Dementia using Structural Brain Imaging for Dementia Work-Up
Niemantsverdriet, E., Feyen, B. F. E., Bastard, N. L., Martin, J., Goeman, J., Deyn, P. P. D., & Engelborghs, S. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-142103 · Cited by 47 · see citing works
Self-citationNEUROPATHOLOGY OF DEMENTING DISORDERS.
Lantos, P. L. (1999) · Brain · doi:10.1093/brain/122.3.581 · Cited by 15 · see citing works
Clinical and laboratory diagnosis of Creutzfeldt-Jakob disease.
Weber, T. (2001) · PubMed · Cited by 10 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Clinical diagnosis of Alzheimer’s disease: Recommendations of the International Working Group
Dubois, B., Villain, N., Frisoni, G. B., Rabinovici, G. D., Sabbagh, M., Cappa, S., Bejanin, A., Bombois, S., Epelbaum, S., Teichmann, M., et al. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00066-1 · Cited by 1,051 · see citing works
“In both situations, pathophysiological AD biomarkers can be positive 87 .”
BackgroundAlzheimer’s disease CSF biomarkers: clinical indications and rational use
Niemantsverdriet, E., Valckx, S., Bjerke, M., & Engelborghs, S. (2017) · Acta Neurologica Belgica · doi:10.1007/s13760-017-0816-5 · Cited by 113 · see citing works
Self-citationConsiderations in the clinical use of amyloid PET and CSF biomarkers for Alzheimer's disease
Leuzy, A., Bollack, A., Pellegrino, D., Teunissen, C. E., Joie, R. L., Rabinovici, G. D., Franzmeier, N., Johnson, K. A., Barkhof, F., Shaw, L. M. J., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.14528 · Cited by 97 · see citing works
Clinical application of CSF biomarkers for Alzheimer's disease: From rationale to ratios
Bouwman, F. H., Frisoni, G. B., Johnson, S. C., Chen, X., Engelborghs, S., Ikeuchi, T., Paquet, C., Ritchie, C. W., Bozeat, S., Quevenco, F., et al. (2022) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12314 · Cited by 95 · see citing works
Self-citationKang, J. H., Korecka, M., Lee, E. B., Cousins, K. A. Q., Tropea, T. F., Chen-Plotkin, A. A., Irwin, D. J., Wolk, D., Brylska, M., Wan, Y., et al. (2023) · Clinical Chemistry · doi:10.1093/clinchem/hvad139 · Cited by 64 · see citing works
Neurogranin as biomarker in CSF is non-specific to Alzheimer's disease dementia
Willemse, E. A. J., Sieben, A., Somers, C., Vermeiren, Y., De Roeck, N., Timmers, M., Van Broeckhoven, C., De Vil, B., Cras, P., De Deyn, P. P., et al. (2021) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2021.08.002 · Cited by 34 · see citing works
Self-citationGossye, H., Van Broeckhoven, C., & Engelborghs, S. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00757 · Cited by 34 · see citing works
Self-citationVacínová, G., Vejražková, D., Rusina, R., Holmerová, I., Vaňková, H., Jarolímová, E., Včelák, J., Bendlová, B., & Vaňková, M. (2020) · Neural Regeneration Research · doi:10.4103/1673-5374.295340 · Cited by 32 · see citing works
AD biomarker discovery in CSF and in alternative matrices
Sancesario, G. M., & Bernardini, S. (2019) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2019.08.008 · Cited by 30 · see citing works
Santangelo, R., Dell’Edera, A., Sala, A., Cecchetti, G., Masserini, F., Caso, F., Pinto, P., Leocani, L., Falautano, M., Passerini, G., et al. (2019) · Current Alzheimer Research · doi:10.2174/1567205016666190725150836 · Cited by 27 · see citing works
Cerebrospinal fluid: A specific biofluid for the biosensing of Alzheimer's diseases biomarkers
Mirzaie, A., Nasrollahpour, H., Khalilzadeh, B., Jamali, A., Spiteri, R., Yousefi, H., Isildak, I., & Rahbarghazi, R. (2023) · Trends in Analytical Chemistry (TrAC) · doi:10.1016/j.trac.2023.117174 · Cited by 26 · see citing works
Patel, K. J., Yang, D., Feldman, H., Hsiung, G. R., Nygaard, H. B., Best, J. R., Dwosh, E., Robillard, J. M., & DeMarco, M. L. (2024) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12463 · Cited by 13 · see citing works
Mathioudakis, L., Dimovasili, C., Bourbouli, M., Latsoudis, H., Kokosali, E., Gouna, G., Vogiatzi, E., Basta, M., Kapetanaki, S., Panagiotakis, S., et al. (2022) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2022.07.002 · Cited by 7 · see citing works
Challenges in Alzheimer’s Disease Diagnostic Work-Up: Amyloid Biomarker Incongruences
Lombardi, G., Pupi, A., Bessi, V., Polito, C., Padiglioni, S., Ferrari, C., Lucidi, G., Berti, V., Cristofaro, M. T. D., Piaceri, I., et al. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200119 · Cited by 5 · see citing works
Performance of novel tau antibodies across multiple modalities for Alzheimer's disease assessment
Trivedi, P., Forrest, K., Fisher, D. W., Winstone, J. K., McMillan, P. J., Valentine, M., Postupna, N. O., Wilson, A. M., Bajwa, T. S., MacCoss, M. J., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70481 · Cited by 5 · see citing works
Fluid Markers of Alzheimer Disease
Sutphen, C. L., Volluz, K., & Tarawneh, R. M. (2025) · Springer eBooks · doi:10.1007/978-3-031-80849-4_8 · Cited by 2 · see citing works
The Change in Dementia Presentation During the Past Decades
Jhang, K.-M., Lee, C.-J., & Chen, Y.-C. (2026) · Springer eBooks · doi:10.1007/978-981-95-5222-1_11
Advancing early detection of Alzheimer's disease: from established biomarkers to future innovations
Qu, L., Wang, Y., Ren, L., Zhang, C., Guo, Z., Zhang, L., Pang, X., & Sha, S. (2026) · International Immunopharmacology · doi:10.1016/j.intimp.2026.117537
- Authors
- Niemantsverdriet, E., Feyen, B. F. E., Le Bastard, N., Martin, J.-J., Goeman, J., De Deyn, P. P., Bjerke, M., & Engelborghs, S.
- Affiliations
- University of Antwerp (BE)
- Reference Center for Biological Markers of Dementia (BIODEM), Laboratory of Neurochemistry and Behavior, and Biobank, Institute Born-Bunge, University of Antwerp, Antwerp, Belgium
- ZNA Middelheim Hospital (BE)
- Corresponding author
- Engelborghs, Sebastiaan
- Venue
- Journal of Alzheimer s Disease
- Publisher
- SAGE Publications
- Published
- 2018-04-10
- Volume
- 63
- Issue
- 1
- Pages
- 373-381
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- PMC
- PMC5900550
- OpenAlex
- W2794653302
- Cited by
- 19
- References
- 36
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 1 · 2023: 2 · 2022: 3 · 2021: 2 · 2020: 2 · 2019: 3 · 2017: 1
- FWCI
- 1.37
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Alzheimer s Disease (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Funders
- Agentschap Innoveren en Ondernemen
- European Federation of Pharmaceutical Industries and Associations (115372)
- Fonds Wetenschappelijk Onderzoek
- Universiteit Antwerpen
- Vlaamse regering
- Instituut Born-Bunge
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Cerebrospinal fluid and hydrocephalus
- Keywords
- cerebrospinal fluid biomarkers
- MeSH terms
- Aged, Aged, 80 and over, Autopsy, Dementia, Diagnosis, Differential, Female, Humans, Male, Middle Aged, Peptide Fragments, Psychiatric Status Rating Scales, Cohort Studies, Biomarkers, Amyloid beta-Peptides, tau Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
